KENILWORTH, N.J. -- Results of a new study
published in the New England Journal of Medicine show
that in patients who have chronic hepatitis C, genotype 1 -- the most common
form of the disease and difficult to treat successfully -- non-Hispanic whites
achieved one of the highest response rates reported to date, but response
rates in African Americans were significantly lower.(1) The findings
challenge much of the current thinking about why African Americans respond
less well to hepatitis C treatment and underscore the need for further
clinical research.
In the large open-label study, non-Hispanic white patients achieved a
sustained virologic response (SVR) rate of 52 percent, which was significantly
higher than the 19 percent seen in African American patients (p < 0.001). SVR
is the sustained undetectability of the hepatitis C virus for six months
following therapy. Lower SVR rates in African Americans, as seen in this
study, also have been seen in past studies using other forms of interferon
therapy, (2,3,4,5) including the newer peginterferon and ribavirin combination
therapies.(6,7)
"The sustained virologic response rates achieved in this study in genotype
1 patients demonstrate that peginterferon alfa-2b and ribavirin combination
therapy is effective," said lead investigator Andrew Muir, MD, assistant
professor of medicine in the Division of Gastroenterology at Duke University Medical
Center in Durham, NC. He noted that the study was conducted in a
"real-world" community setting, rather than in a more restrictive clinical
trial. "However, the lower response rate in African Americans poses a
critical challenge because even with the best therapies currently available,
African American patients clearly have a lower response rate."
In the study, 100 African American and 100 non-Hispanic white patients
with chronic hepatitis C, genotype 1, were treated with a regimen of
peginterferon alfa-2b (1.5 mcg/kg/weekly) and 1,000 mg of ribavirin daily for
the first 12 weeks and then 800 mg daily thereafter, for a total of 48 weeks.
Growth factors were not used. The current U.S. label for peginterferon alfa-
2b (1.5 mcg/kg/week) recommends that it be used in combination with 800 mg of
ribavirin daily. The investigators analyzed a number of variables, including
patients' socio-demographic and clinical characteristics, and found that only
race was significantly associated with the difference in SVR rates.
The study demonstrated the safety and tolerability of peginterferon alfa-
2b and ribavirin combination therapy in these patients, and showed that the
rates and types of adverse events were similar in the African American and
non-Hispanic white patient groups. Importantly, the rate of dose reduction of
peginterferon alfa-2b because of neutropenia was similar in the two groups (13
vs. 14 percent, respectively) as was the rate of discontinuation due to
neutropenia (4 vs. 3 percent, respectively). Neutropenia often is a concern
when treating African Americans, as seen in previous clinical studies.(6,8)
Muir said the reasons for the different responses seen in the racial
groups remains unknown, but the study results counter at least some previously
held hypotheses. For example, some suggested the disparity could be due to a
higher prevalence of hepatitis C, genotype 1, in African Americans, but in
this study 98 percent of both racial groups had that form of the virus.
Further analyses showed that other variables -- including age, sex, education,
body weight, initial viral load, duration of HCV infection and other clinical
factors -- had no significant effect on response. "Showing these other
factors are not the reason for the difference in response rates adds to our
understanding of the disease and is important in furthering research to
identify what factors actually are responsible. We can speculate about what
those causes might be, but we need additional clinical studies to get real
answers," he said.
"While we are concerned about these findings in African Americans, it is
critical to point out that many of these patients do, in fact, respond to
hepatitis C treatment, so it is vitally important for an infected individual
to aggressively pursue, with their physician, evaluation for therapy," urged
Jonathan McCone, MD, director of the Mount Vernon Endoscopy Center in Alexandria,
Va., and a participating investigator in the study. He noted that hepatitis
C, the most common blood-borne infection in America, affects approximately 4
million people, including a disproportionately high percentage of African
Americans. Chronic hepatitis C infection substantially increases the risk of
cirrhosis and liver cancer, and is the most frequent indication for liver
transplantation among adults. "Timely therapy can help achieve a sustained
virologic response," McCone said, "and patients can improve their chances of
achieving an SVR by adhering to therapy."
Muir concurred, noting that the study found a higher SVR rate (23
percent) among African Americans who completed the full course of therapy.
The importance of adhering to treatment is exemplified by Jackie Boykin,
RN, 41, an African-American woman who contracted hepatitis C in the course
of her work as a nurse. While not a participant in the study by Muir and his
colleagues, she was treated at Duke University Medical Center. In 2002,
Boykin received combination therapy with PEG-INTRON (peginterferon alfa-2b)
Powder for Injection and REBETOL (ribavirin, USP) capsules. She achieved
an SVR and has been virus free for nearly one-and-a-half years. As a result
of her experience, Boykin counsels many patients with hepatitis C to stay with
the therapy "because compliance is so important to treating the disease," she
said.
"I found the Schering-Plough PEG-INTRON Web site very helpful, and the
support I received from the nurses in the Be In Charge program helped me stay
on therapy." Schering-Plough's Be In Charge hepatitis C patient-support
program provides educational materials and telephone contact with registered
nurse counselors skilled in the management of hepatitis C. "Support from
family, the community and medical professionals is critical for hepatitis C
patients," Boykin said. She continues to attend a hepatitis C patient support
group at Duke University Medical Center.
References:
(1) Muir AJ, Bornstein JD, Killenberg PG, for the Atlantic Coast Hepatitis
Treatment Group. Peginterferon alfa-2b and ribavirin for the treatment of
chronic hepatitis C in African Americans and Non-Hispanic Whites. N Engl J
Med 2004; 350(22):27-33.
(2) Reddy KR, Hoofnagle JH, Tong MJ, Lee WM, Pockros P, Heathcote EJ,
Albert D, Joh T. Racial differences in responses to therapy with interferon in
chronic hepatitis C. Hepatology 1999; 30:787-93.
(3) Kinzie JL, Naylor PH, Nathani MG, Peleman RR, Ehrinpreis MN, Lybik M,
Turner JR, Janisse JJ, Massanari M, Mutchnick MG. African Americans with
genotype 1 treated with interferon for chronic hepatitis C have a lower end of
treatment response than Caucasians. J Viral Hepat 2001;8:264-9.
(4) De Maria N. Colantoni A. Idilman R. Friedlander L. Harig J. Van Thiel
DH. Impaired response to high-dose interferon treatment in African-Americans
with chronic hepatitis C. Hepatogastroenterology 2002;49:788-92.
(5) McHutchison JG, Poynard T, Pianko S, Gordon SC, Reid AE, Dienstag J,
Morgan T, Yao R, Albrecht J. The impact of interferon plus ribavirin on
response to therapy in black patients with chronic hepatitis C.
Gastroenterology 2000;119:1317-23.
(6) Howell CD, Jeffers LS, Hu S, Lopez-Talavera JC. Safety and adherence
to peginterferon alfa-2a (40KD) plus ribavirin (RBV) in black Americans with
chronic hepatitis C (CHC) HCV genotype 1. Poster presentation M1236 (Abstract
No. 106885) at Digestive Disease Week, New Orleans, LA, May 15-20, 2004.
(7) Jeffers LJ, Cassidy W, Howell C, Reddy R, Sheridan S, Ho I, Khouri S,
Harb G. Peginterferon alfa-2a (40kd) (Pegasys) in combination with ribavirin
in African American and Caucasian patients with chronic hepatitis C virus
genotype 1: results of a multicenter study. Abstract 71, oral presentation
at: 54th annual meeting of the American Association for the Study of Liver
Diseases, Boston, MA, October 24-28, 2003.
(8) Howell C, Jeffers LJ, Cassidy W, Reddy R, Sheridan S, Ho I, Khouri S,
Harb G. Peginterferon alfa-2a (40kd) (Pegasys) in combination with ribavirin
in African American and Caucasian patients with chronic hepatitis C HCV
genotype 1: safety and tolerability. Abstract 332, poster presentation at:
54th annual meeting of the American Association for the Study of Liver
Diseases, Boston, MA, October 24-28, 2003.
Source: Schering-Plough Corporation
The Evolution of Health Care Environmental Hygiene: A Long Overdue Shift in Infection Control
September 5th 2024This new column, Clean Hospital with Alexandra Peters, PhD, explores advancements in health care environmental hygiene, highlighting its growing recognition as a key component of infection prevention and honoring pioneers like Professor Stephanie Dancer.
New UV-C Disinfection Technology for Ultrasound Probes Earns FDA Clearance
September 4th 2024Chronos, a chemical-free UV-C disinfection device for ultrasound probes, received FDA clearance. It offers health care professionals a fast, automated solution to reduce cross-contamination and improve infection prevention.
Addressing Sterile Processing Instrument Errors With Advanced Technology and Data Insights
September 3rd 2024Surgical instrument errors, often linked to visualization failures during sterile processing, pose significant risks to patient safety and OR efficiency. Advanced technologies, including AI, are essential for reducing these errors and improving overall outcomes in sterile processing departments.